Celebrex Cases in Jeopardy as Judge Excludes Plaintiffs' Experts

SAN FRANCISCO - Allegations that Celebrex can cause cardiovascular problems in patients who take the drug at 200 milligram doses may be thrown out after a federal judge ruled that testimony supporting the theory is inadmissible under Daubert. In Re: Bextra and Celebrex Marketing Sales Practices and Product Liability Litigation, MDL No. 1699 (N.D. Calif.).

Judge Charles R. Breyer issued an opinion Nov. 19, excluding testimony from two plaintiffs' experts who challenged the significant amount of scientific and epidemiological study indicating that there is no increased risk of cardiovascular injury at the recommended dosage.

The decision comes after a three-day …